Deirdre Sawinski1, Nikunjkumar Patel, Brenda Appolo, Roy Bloom. 1. 1 Renal Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia PA. 2 Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Abstract
BACKGROUND: Hepatitis C virus (HCV) infection is prevalent in the renal transplant population but direct acting antiviral agents (DAA) provide an effective cure of HCV infection without risk of allograft rejection. METHODS: We report our experience treating 43 renal transplant recipients with 4 different DAA regimens. RESULTS: One hundred percent achieved a sustained viral response by 12 weeks after therapy, and DAA regimens were well tolerated. Recipients transplanted with a HCV+ donor responded equally well to DAA therapy those transplanted with a kidney from an HCV- donor, but recipients of HCV+ organs experienced significantly shorter wait times to transplantation, 485 days (interquartile range, 228-783) versus 969 days (interquartile range, 452-2008; P = 0.02). CONCLUSIONS: On this basis, we advocate for a strategy of early posttransplant HCV eradication to facilitate use of HCV+ organs whenever possible. Additional studies are needed to identify the optimal DAA regimen for kidney transplant recipients, accounting for efficacy, timing relative to transplant, posttransplant clinical outcomes, and cost.
BACKGROUND:Hepatitis C virus (HCV) infection is prevalent in the renal transplant population but direct acting antiviral agents (DAA) provide an effective cure of HCV infection without risk of allograft rejection. METHODS: We report our experience treating 43 renal transplant recipients with 4 different DAA regimens. RESULTS: One hundred percent achieved a sustained viral response by 12 weeks after therapy, and DAA regimens were well tolerated. Recipients transplanted with a HCV+ donor responded equally well to DAA therapy those transplanted with a kidney from an HCV- donor, but recipients of HCV+ organs experienced significantly shorter wait times to transplantation, 485 days (interquartile range, 228-783) versus 969 days (interquartile range, 452-2008; P = 0.02). CONCLUSIONS: On this basis, we advocate for a strategy of early posttransplant HCV eradication to facilitate use of HCV+ organs whenever possible. Additional studies are needed to identify the optimal DAA regimen for kidney transplant recipients, accounting for efficacy, timing relative to transplant, posttransplant clinical outcomes, and cost.
Authors: Junichiro Sageshima; Christoph Troppmann; John P McVicar; Chandrasekar Santhanakrishnan; Angelo M de Mattos; Richard V Perez Journal: Transplantation Date: 2018-07 Impact factor: 4.939
Authors: Christian Corbin Frye; Jason M Gauthier; Amit Bery; William D Gerull; Deniz B Morkan; Jingxia Liu; M Shea Harrison; Yuriko Terada; Judith E Van Zanden; Gary F Marklin; Michael K Pasque; Ruben G Nava; Bryan F Meyers; Alexander G Patterson; Benjamin D Kozower; Ramsey Hachem; Derek Byers; Chad Witt; Hrishikesh Kulkarni; Daniel Kreisel; Varun Puri Journal: Clin Transplant Date: 2020-12-14 Impact factor: 2.863
Authors: Andrew A Li; George Cholankeril; Xingxing S Cheng; Jane C Tan; Donghee Kim; Alice E Toll; Satheesh Nair; Aijaz Ahmed Journal: Diseases Date: 2018-07-10
Authors: Dimitrios Farmakiotis; Zoe Weiss; Amy L Brotherton; Paul Morrissey; Reginald Gohh; Kendra Vieira; Lynn E Taylor; Joseph M Garland Journal: Case Reports Hepatol Date: 2020-01-29